Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 11/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026536 | 0.88 | PLG (0.36) | KMT2AMEN1ALDH1A1CYP2C9VCP | |
| SCHEMBL5025670 | 0.83 | KMT2A (0.42) | KMT2AMEN1ALDH1A1CYP2C9VCP | |
| SCHEMBL5030007 | 0.76 | HSD11B1 (0.39) | KMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL5025529 | 0.73 | TAS2R14 (0.40) | KMT2AMEN1ALDH1A1TAS2R14PLG | |
| SCHEMBL5025534 | 0.73 | TAS2R14 (0.40) | KMT2AMEN1ALDH1A1TAS2R14PLG | |
| SCHEMBL5762614 | 0.73 | HRH4 (0.31) | — | |
| SCHEMBL11217670 | 0.72 | CXCR4 (0.56) | KMT2AMEN1ALDH1A1CYP2C9VCP | |
| SCHEMBL11217673 | 0.72 | CXCR4 (0.56) | KMT2AMEN1ALDH1A1CYP2C9VCP | |
| SCHEMBL5025599 | 0.72 | PLG (0.38) | KMT2AMEN1ALDH1A1CYP2C9VCP | |
| SCHEMBL5024109 | 0.72 | CHRM4 (0.39) | KMT2AMEN1ALDH1A1CYP2C9VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442791-B2 | Aminoalkylamide substituted cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1667962-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005028427-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | LSS, CYP51A1, CYP46A1 | KMT2A 1378/4885MEN1 989/4885ALDH1A1 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.